Akebia Therapeutics
AKBA
94 hedge funds and large institutions have $147M invested in Akebia Therapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 12 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 27
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 92 → 94 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $191M → $147M (-$43.9M)
41% less call options, than puts
Call options by funds: $1.94M | Put options by funds: $3.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$5.43M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.91M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.87M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.51M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$934K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$12.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.77M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$4.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.62M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$2.08M |
AKBA Hedge Fund Activity: Q2 2016 in Review
94 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2016, worth a combined $147M — down 23% from $191M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AKBA positions and 12 closed out — a net gain of 2 holders — while 38 added to existing stakes and 27 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $5.43M. The largest seller was Visium Asset Management, cutting an estimated $12.1M.
- 94 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2016, up from 92 in Q1 2016.
- Funds reported $147M of Akebia Therapeutics stock for Q2 2016, down 23% quarter-over-quarter.
- 14 funds opened new Akebia Therapeutics positions in Q2 2016 and 12 closed out, a net change of +2 holders.
- The largest Akebia Therapeutics buyer in Q2 2016 was Avoro Capital Advisors, an estimated $5.43M added.
- The largest Akebia Therapeutics seller in Q2 2016 was Visium Asset Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2016.